CRISPR Therapeutics AG — Director's Dealing 2018

Jan 18, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2018-01-16

Reporting Person: Dylan-Hyde Tyler (Chief Legal Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-01-16	Common Shares	S	45000	$28.00	Disposed	25204	Direct
2018-01-16	Common Shares	M	1110	$12.57	Acquired	26314	Direct
2018-01-16	Common Shares	S	1110	$28.24	Disposed	25204	Direct
2018-01-16	Common Shares	M	19890	$12.57	Acquired	45094	Direct
2018-01-16	Common Shares	S	19890	$28.10	Disposed	25204	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-01-16	Stock Option (Right to Buy)	$12.57	M	1110	Disposed	2026-07-15	Common Shares (1110)	Direct
2018-01-16	Stock Option (Right to Buy)	$12.57	M	19890	Disposed	2026-07-15	Common Shares (19890)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $28.75, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.85 to $28.75, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

F4: This option was granted on July 15, 2016 with respect to 53,333 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016.

F5: This performance-based option was granted on July 15, 2016 with respect to 26,667 Common Shares with 100% of the shares vesting within 12 months of the date of grant, subject to the satisfaction of mutually agreed upon performance metrics.